Oxford University spinout raises another £20 million for vaccine program

16 January 2018

Oxford University spinout Vaccitech has completed a series A financing round, securing £20 million ($27 million) in new money from Google’s venture capital arm GV, Sequoia China, and existing backer Oxford Sciences Innovation.

Based at the Oxford Science Park, the firm is working on a universal flu vaccine and five other vaccine-related products, based on a technology for inducing cellular immune responses using non-replicating viral vectors.

Vaccitech’s universal influenza vaccine is being tested in a Phase IIb efficacy trial, in which 862 people are enrolled in the first year of a two-year study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK